Navigation Links
Agendia Presents Data Supporting MammaPrint's Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
Date:3/11/2009

HUNTINGTON BEACH, California, and AMSTERDAM, The Netherlands, March 11 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia and the Netherlands Cancer Institute will present data from multiple studies at the 2009 St.Gallen Breast Cancer Conference. The St. Gallen Breast Cancer Conference, one of the premiere conferences in breast cancer research worldwide, takes place March 11th-14th, 2009 in St.Gallen, Switzerland.

The study results further underpin the predictive and prognostic power of Agendia's breast cancer recurrence test, MammaPrint(R) and will be discussed at the following poster sessions:

Thursday, 12 March 2009

Poster 0063

Comparison of MammaPrint and TargetPrint Results with Clinical Parameters in German Patients (PATH) with Early Stage Breast Cancer

G. Kunz, T. Dimpfl, C. Jakisch, R. Buttner, F. A. de Snoo, O. Krijgsman, E. van Lienen, A. Glas, and R. Bender.

Thursday, 12 March 2009

Poster 0071

The 70 Gene-MammaPrint Profile Allows to Identify a Subgroup of Good-Prognostic Patients with Primary Breast Cancer and 4-9 Positive Lymph Nodes

M. Saghatchian, S. Mook, G. Pruneri, G. Viale, A. Glas, I. Eekhout, M. Knauer, and LJ van 't Veer.

Thursday, 12 March 2009

Poster 0072

The 70-gene MammaPrint Prognosis Signature for Optimal Risk Stratification in Endocrine Responsive Breast Cancer

M Knauer, EJT Rutgers, S Mook, F Cardoso, MJ van de Vijver, G Viale, AM Glas, M. Saghatchian, M Kok, JM Bueno-de-Mesquita, SC Linn and LJ van 't Veer.

Thursday, 12 March 2009

Poster 0073

The 70-gene MammaPrint Signature Is Predictive for Chemotherapy Benefit in Early Breast Cancer

M Knauer, ME Sraver, EJT Rutgers, RA Bender, F Cardoso, S Mook, MJ van de Vijver, M. Saghatchian, RHT Koornstra, JM Bueno-de-Mesquita, S Rodenhuis, SC Linn and LJ van 't Veer.

Thursday, 12 March 2009

Poster 0074

Early Prognosis Prediction: MammaPrint on Core-needle biopsies

F. de Snoo, A. Glas, A. Floore, J. Mayordomo, A. Modollel, C. Rolfo, LJ van 't Veer, E. Rutgers, S. Rodenhuis, and R. Bender.

Thursday, 12 March 2009

Poster 0075

Use of the Genomic Test MammaPrint in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients

G. Kunz, A. Glas and F. de Snoo, I. Simon.

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-those patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test result provides a doctor with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
2. Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
3. Agendia Appoints VP of Business Development
4. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
5. Agendia Appoints New Chief Financial Officer
6. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
7. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
8. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
9. Agendia BV Appoints Clinical and Scientific Advisory Board
10. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
11. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
Breaking Biology Technology:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
Breaking Biology News(10 mins):